GoCo Health Innovation City is pleased to announce that Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech company developing innovative treatments for rare and common cardiovascular diseases, will be relocating to a new office space within GoCo Health Innovation City in June 2024. This move marks a significant milestone for both Cereno Scientific and GoCo Health Innovation City, furthering the mission to cultivate a collaborative ecosystem that drives health innovation forward.
Cereno Scientific's decision to join GoCo Health Innovation City underscores GoCo’s commitment to provide an inspiring environment for researchers, entrepreneurs, and talents from around the world. This strategic relocation aims to enhance Cereno’s research capabilities and foster greater collaboration within the GoCo community.
- Cereno Scientific's transition from the BioVentureHub to a larger space at GoCo Health Innovation City is a testament to the success of our collaborative ecosystem and our strong partnership with AstraZeneca. We're truly inspired by Cereno Scientific's progress and eagerly look forward to their continued growth within our facilities and community, says Marie Uddenmyr, Director of Corporate Relations at GoCo Health Innovation City.
Cereno Scientific has a remarkable pipeline that includes late-stage Phase II drug candidate CS1, an HDAC inhibitor with epigenetic effects for the treatment of Pulmonary Arterial Hypertension (PAH), as well as CS014, another HDAC inhibitor with epigenetic effects, for thrombosis prevention. Additionally, CS585, a novel IP receptor agonist, is in preclinical development with potential applications in Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding.
Recently, Cereno Scientific reported positive findings from its ongoing study, indicating a potential clinical benefit of CS1 in patients with severe PAH. Moreover, Cereno was granted FDA approval for Expanded Access for CS1 on January 30, a significant milestone towards addressing the urgent medical needs of patients with PAH. Study completion and top-line results are anticipated in Q3 2024.
- After eight successful years at AstraZeneca's BioVentureHub, Cereno Scientific's relocation to GoCo Health Innovation City represents the next chapter in our growth journey. We are excited to continue our trajectory in this inspiring environment alongside other fast-growing life science companies, says Sten R. Sörensen, CEO of Cereno Scientific.
About Cereno Scientific
Cereno Scientific develops innovative treatments for cardiovascular diseases, focusing on both common and rare conditions. Their lead drug candidate, CS1, is in a Phase II study for pulmonary arterial hypertension (PAH) and has shown promising preliminary results. Cereno collaborates with Abbott and the University of Michigan, developing additional drug candidates like CS014 for thrombosis prevention and CS585 for potential use in pulmonary hypertension. The FDA's Expanded Access Program now allows PAH patients to access CS1. Headquartered in Gothenburg, Sweden, with a subsidiary in Boston, Cereno is listed on Nasdaq First North (CRNO B).
About GoCo Health Innovation City
GoCo Health Innovation City is a leading life sciences destination in Gothenburg, Sweden, designed to foster innovation and collaboration among researchers, entrepreneurs, and industry leaders. With state-of-the-art facilities and a vibrant community, GoCo aims to drive breakthroughs in health and life sciences.
We use cookies to ensure that we give you the best experience on our website. By continuing to browse the site you are agreeing to our use of cookies. Read more about our data and privacy policy here.
OK